Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases

BMC Gastroenterology

Xu-Dong Qu¹  Meng-Su Zeng²  Hao Liu²  Cai-Zhong Chen²  Sheng-Xiang Rao² 

[1] Department of Interventional Radiology, Zhongshan Hospital, Fudan University, and Shanghai Medical Imaging Institute, Shanghai, People’s Republic of China;Department of Diagnostic Radiology, Zhongshan Hospital, Fudan University, and Shanghai Medical Imaging Institute, Shanghai, People’s Republic of China

关键词: Inter-observer analysis;    Colorectal hepatic metastasis;    HCC;    Perfusion Imaging;    3D Magnetic Resonance Imaging;   

Others  :  858112
DOI  :  10.1186/1471-230X-13-53

 received in 2012-06-04, accepted in 2013-03-21,  发布年份 2013

【 摘 要 】

Background

Three-dimensional (3D) whole-liver perfusion magnetic resonance(MR) imaging with parallel imaging, a novel imaging method to characterize tumor vascularization in vivo, has recently been applied to comprehensively image perfusion changes in large tumors. Coupled with new perfusion software, this technique enables motion correction, registration, and evaluation of perfusion MR parameters. The purpose of this study was to assess the feasibility of 3D whole-liver perfusion MR, for imaging hepatocellular carcinoma (HCC) and colorectal hepatic metastases (CRHM).

Methods

26 patients with hepatic tumors (10 HCC; 16 CRHM) were subjected to 3D whole-liver perfusion MR with a temporal resolution of 3.7 seconds. The following estimated perfusion parameters were measured: the volume transfer constant K^trans (min^-1); the volume (V_e) of extravascular extracellular space (EES) per volume unit of tissue; and the flux rate constant between EES and plasma K_ep (min^-1). Statistical analysis was conducted to investigate inter-observer characteristics and significance of the measured parameters.

Results

Inter-observer agreement analysis (95% limits of agreement) yielded a mean difference of −0.0048 min^-1 (−0.0598 ~ 0.0502) for K^trans , -0.0630 ml (−0.5405 ~ 0.4145) for V_e, and −0.0031 min^-1 (−0.0771 ~ 0.0709) for K_ep respectively. When comparing images from patients with HCC vs. CRHM, significant differences were seen for the mean K^trans (p = 0.017), but not for V_e(p = 0.117) or K_ep(p = 0.595).

Conclusion

Herein we show that 3D whole-liver MR perfusion imaging with semi-automatic data analysis is feasible and enables the reliable quantitative evaluation of the perfusion parameters for HCCs and CRHMs.

【 授权许可】

   
2013 Rao et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Pandharipande PV, Krinsky GA, Rusinek H, Lee VS: Perfusion imaging of the liver: current challenges and future goals. Radiology 2005, 234(3):661-673.
• [2]Schirin-Sokhan R, Winograd R, Roderburg C: Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol 2012, 18(6):541-545.
• [3]Goetti R, Leschka S, Desbiolles L: Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol 2010, 45(7):419-426.
• [4]Ng CS, Chandler AG, Wei W: Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011, 260(3):762-770.
• [5]Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM: Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 2010, 194(2):W134-140.
• [6]Koh TS, Thng CH, Lee PS, Hartono S, Rumpel H, Goh BC, Bisdas S: Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008, 249(1):307-320.
• [7]Morgan B, Thomas AL, Drevs J: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21(21):3955-3964.
• [8]Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA, Taouli B: Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging–initial experience. Radiology 2008, 246(3):926-934.
• [9]Tofts PS, Brix G, Buckley DL: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10(3):223-332.
• [10]Rosen MA, Schnall MD: Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007, 13((2 Pt 2):770s-776s.
• [11]Reitan NK, Thuen M, Goa PE, de Lange DC: Characterization of tumor microvascular structure and permeability: comparison between magnetic resonance imaging and intravital confocal imaging. J Biomed Opt 2010, 15(3):036004.
• [12]Hayes C, Padhani AR, Leach MO: Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002, 15(2):154-163.
• [13]Galbraith SM, Lodge MA, Taylor NJ: Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002, 15(2):132-142.
• [14]Jackson A: Imaging microvascular structure with contrast enhanced MRI. Br J Radiol 2003, 76(2):S159-S173.
• [15]Ueda T, Oda T, Kinoshita T: Neovascularization in pancreatic ductal adenocarcinoma: Microvessel count analysis, comparison with non-cancerous regions and other types of carcinomas. Oncol Rep 2002, 9(2):239-245.
• [16]Duarte IG, Bufkin BL, Pennington MF: Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998, 115(3):652-658.
• [17]Weidner N, Folkman J, Pozza F: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 16;84(24):1875-1887.
• [18]Vermeulen PB, Verhoeven D, Hubens G: Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995, 6(1):59-64.
• [19]Goel S, Duda DG, Xu L: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91(3):1071-1121.
• [20]Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, Gillespie GY: High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med 2009, 61(3):615-625.
• [21]Zhu AX, Sahani DV, Duda DG: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035.
• [22]Gaustad JV, Benjaminsen IC, Ruud EB, Rofstad EK: Dynamic contrast-enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions. J Magn Reson Imaging 2007, 26(1):133-143.